Roueen Rafeyan, MD, DFAPA, FASAM

The Psychiatric Times Substance Use Section Editor reflects on the theme of the 2024 Annual Meeting, plus what he is most excited about in psychiatry.

Psychiatric Times® Substance Use Section Editor Roueen Rafeyan, MD, DFAPA, FASAM, weighs in.

Psychiatric Times’ Substance Use Section Editor weighs in on the FDA approval of the first naloxone product for nonprescription use.

Clinicians are often busier than usual during the holidays. How can you find the time to spend quality time with your loved ones?